Oric Pharmaceuticals, Inc. current report, 03 August 2020

Full document

ORIC Pharmaceuticals, Inc. Form 8-K Summary

Business Context and Reporting Period

ORIC Pharmaceuticals, Inc. filed a Form 8-K dated August 5, 2020, reporting events occurring August 3, 2020. The filing references financial results for the fiscal quarter ended June 30, 2020, but the underlying results press release is not included in the provided filing text.

Transaction and Key Financial Information

  • ORIC entered into an agreement with Mirati Therapeutics, Inc. for an exclusive, worldwide license to develop and commercialize Mirati’s allosteric polycomb repressive complex 2 (PRC2) inhibitors for all indications.
  • As consideration, ORIC issued 588,235 shares of common stock to Mirati on August 3, 2020.
  • The shares were valued at $34.00 per share, representing a 10% premium to ORIC’s 60-day trailing volume-weighted average trading price.
  • The implied value of the equity consideration was approximately $20.0 million.
  • The shares were issued in a private placement under Section 4(a)(2) of the Securities Act and were not registered at issuance.
  • Mirati is subject to transfer restrictions for 18 months following the stock issuance agreement. The parties agreed to negotiate and enter into a registration rights agreement.
  • The provided text does not state revenue, net income or loss, cash flow, margins, debt, cash balance, liquidity runway, or other quarterly financial metrics.

Material Changes, Outlook, and Risks

  • The license transaction expanded ORIC’s development and commercialization rights to PRC2 inhibitors and resulted in equity dilution of 588,235 shares.
  • The filing does not provide specific financial guidance, clinical timelines, milestone obligations, contingent payments, or management outlook for the licensed programs.
  • Key risks include development and regulatory uncertainty for the PRC2 inhibitors, potential future dilution or financing needs, and the absence of an executed registration rights agreement as of the filing.
  • The filing’s results announcement and transaction announcement were furnished under Items 2.02 and 7.01 and were stated not to be “filed” for purposes of Section 18 liability, except as expressly incorporated by reference.

Important Facts for Investors to Verify

  1. Review Exhibit 99.1 for the complete quarter-ended June 30, 2020 financial results, including cash and operating expenses.
  2. Review Exhibit 99.2 and the license agreement for the PRC2 program scope, development obligations, milestones, royalties, and other consideration.
  3. Confirm the final terms and timing of the registration rights agreement with Mirati.
  4. Assess the effect of the 588,235-share issuance on ORIC’s fully diluted share count and ownership structure.